NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
Sanofi notified Nurix that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.
Sanofi notified Nurix that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.